Attached Documents
- Opinion
- JLI’s complaint
- FDA’s motion for summary judgment
- JLI’s opposition cross-motion for summary judgment
- FDA’s opposition to JLI’s cross-motion and reply in support of its motion
- JLI’s reply
- JLI’s Oct. 16, 2023, notice of supplemental authority
- FDA’s response
- FDA’s notice of submission of documents for in camera review
- JLI’s response